Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.

Manganoni AM, Farisoglio C, Ferrari V, Zaniboni A, Beretta G, Meriggi F, Calzavara-Pinton P.

Ann Surg Oncol. 2009 Jan;16(1):224-5. doi: 10.1245/s10434-008-0200-z. Epub 2008 Nov 7. No abstract available.

PMID:
18989724
2.

Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.

Iacovelli L.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):31-3.

3.

Clinical management of EGFRI dermatologic toxicities: the nursing perspective.

Purdom M, Ohinata A.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):29-30.

4.

Clinical management of EGFRI dermatologic toxicities: the European perspective.

Segaert S, Van Cutsem E.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):22-6.

5.

[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].

Reimer G, Brudler O, Heinrich B, Bangerter M.

MMW Fortschr Med. 2008 Dec 4;150(49-50):37-8, 40. German. No abstract available.

PMID:
19133368
6.

Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.

Pomerantz RG, Chirinos RE, Falo LD Jr, Geskin LJ.

Arch Dermatol. 2008 Jul;144(7):949-50. doi: 10.1001/archderm.144.7.949. No abstract available.

PMID:
18645156
7.

Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.

Yamazaki N, Muro K.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):27-8.

8.

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

Tan EH, Chan A.

Ann Pharmacother. 2009 Oct;43(10):1658-66. doi: 10.1345/aph.1M241. Epub 2009 Sep 15. Review.

PMID:
19755624
9.

Treatment of epidermal growth factor receptor inhibitor-induced skin toxicities: do the data support the current practice?

Cotliar J.

Support Care Cancer. 2011 Oct;19(10):1481-2. doi: 10.1007/s00520-011-1234-5. Epub 2011 Aug 4. No abstract available.

PMID:
21814780
10.

EGFR-targeted therapy and related skin toxicity.

Morse L, Calarese P.

Semin Oncol Nurs. 2006 Aug;22(3):152-62. Review.

PMID:
16893744
11.

Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.

Fox LP.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):26-34. Review.

12.

Successful treatment with adapalene of cetuximab-induced acneiform eruptions.

Taguchi K, Fukunaga A, Okuno T, Nishigori C.

J Dermatol. 2012 Sep;39(9):792-4. doi: 10.1111/j.1346-8138.2011.01424.x. Epub 2011 Dec 14. No abstract available.

PMID:
22168666
13.

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME.

Oncologist. 2007 May;12(5):610-21. Review.

14.

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B.

Br J Dermatol. 2004 Jul;151(1):238-41. No abstract available.

PMID:
15270903
15.

Clinical management of EGFRI dermatologic toxicities: US perspective.

Lacouture ME, Cotliar J, Mitchell EP.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21.

16.

Cetuximab-induced acneiform eruption and the response to isotretinoin.

Vezzoli P, Marzano AV, Onida F, Alessi E, Galassi B, Tomirotti M, Berti E.

Acta Derm Venereol. 2008;88(1):84-6. doi: 10.2340/00015555-0330. No abstract available.

17.

Rosaceiform eruption induced by cetuximab.

Fernández-Torres R, Martínez Gomez W, Cuevas Santos J, Paradela S, Fonseca Capdevila E.

Eur J Dermatol. 2010 May-Jun;20(3):392-3. doi: 10.1684/ejd.2010.0900. Epub 2010 Feb 22. No abstract available.

PMID:
20172848
18.

Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.

Boucher J, Olson L, Piperdi B.

Clin J Oncol Nurs. 2011 Oct;15(5):501-8. doi: 10.1188/11.CJON.501-508.

PMID:
21951736
19.

How to integrate biologicals in the continuum of care.

Venugopal B, Cassidy J.

Eur J Cancer. 2009 Sep;45 Suppl 1:57-69. doi: 10.1016/S0959-8049(09)70017-6. Review. No abstract available.

PMID:
19775605
20.

Toward evidence-based management of the dermatologic effects of EGFR inhibitors.

LoRusso P.

Oncology (Williston Park). 2009 Feb;23(2):186-94.

Supplemental Content

Support Center